Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Malignant GliomaGlioblastoma
Interventions
DRUG

hEGFRvIII-CD3 (BRiTE)

Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER